Immunotherapy plus chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if the combination shrinks tumors more effectively and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be generally healthy and able to perform daily activities with mild or no help (ECOG score 0 or 1).
- You must have a type of esophageal cancer called squamous cell carcinoma that is locally advanced but can be surgically removed.
- Your cancer stage must be cT1-2N1-3M0 or cT3-4aN0-3M0, meaning it has spread to nearby lymph nodes but not to distant organs.
- You must be expected to have surgery after the pre-surgery treatment, with the goal of removing all visible cancer.
- You must not have received any prior cancer treatment for esophageal cancer.
- Your organs must be functioning well enough to handle the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
This trial tests whether giving a combination of two immunotherapy drugs, a targeted therapy, and chemotherapy before surgery helps shrink esophageal tumors and improve outcomes. It might make surgery more effective for patients with resectable esophageal cancer.
This trial tests whether combining two immunotherapy drugs (which boost your immune system to fight cancer) with a standard chemotherapy drug before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if this approach shrinks the tumor and helps you live longer.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Hear when a new Resectable Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.